CClinicalTrials.gg
Status unknownNCT01494974Updated Apr 8, 2014

Comparison of the Ahmed Glaucoma Valve FP7 and FP8 in Pediatric Glaucoma

A Phase 4 interventional study of FP7 Ahmed Glaucoma Drainage Implant and FP8 Glaucoma Drainage Implant in Pediatric Glaucoma, sponsored by Federal University of São Paulo. Status unknown at 1 site in Brazil. Open to participants aged Up to 10 Years. Per ClinicalTrials.gov, last updated 2014-04-08.

Sponsored by Federal University of São Paulo · Phase 4, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Apr 2014), so the status shown — last known as Recruiting — may be out of date.
Phase
Phase 4
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
Up to 10 Years
Sex
All
01

Study summary

The purpose of this study is to compare the success rates and complications of two models of Ahmed glaucoma implants (FP7 and FP8) in patients with pediatric glaucoma.

Read the detailed description

INTRODUCTION

The drainage implants have become an important alternative in the treatment of pediatric glaucoma refractory to angular and filtration surgery or medical therapy (1). Such implants drain the aqueous humor from the anterior chamber of the eye to a plate positioned above the sclera, between the rectus muscles. The aqueous humor goes through the pseudocyst that forms around the plate by passive diffusion and is drained by the venous capillaries and lymphatic system.

The Ahmed drainage implant (New World Medical, Inc., Rancho Cucamonga, CA, USA) is a device with flow restrictors, which decreases the incidence of postoperative complications such as hypotony (2-3). It is made of silicone and comes in two sizes. The FP7 model has a surface of 184 mm2, 13mm wide and 16mm long. The FP8 model presents 96mm2 surface, 9.6 mm wide and 10mm long.

Studies in animals and adult humans suggest that the surface area of the implant plate is directly related to the amount of aqueous fluid drained through the same (4-7). In contrast, a very large implant can result in the extrusion of the same, uncontrolled intraocular pressure, corneal injury by endothelial touch, patient discomfort and ocular motility problems. The use of pediatric size implants in small eyes can avoid such complications. A high rate (34.8%) of anterior plate of the tubes in children under 2 years of age has been reported (8-9). On the other hand, the use of pediatric implante may affect the control of intraocular pressure (IOP) due to reduced drainage area (10), especially in eyes with increasing axial diameter, a result of increased eye pressure that happens in children with glaucoma. However, there is no study in the literature comparing different sizes of drainage implants in pediatric patients.

A study to compare the success rates and complications between FP7 and FP8 models is essential in order to standardize a conduct in choosing the type of implant. Currently, the choice of the drainage implant model to be used in every child lies on the free choice and personal preference of the surgeon. There is no standard procedure, based on scientific evidence for this choice.

OBJECTIVES

Compare the success rates and complications of two models of Ahmed drainage implant (FP7 and FP8) in patients with pediatric glaucoma.

MATERIALS AND METHODS

This clinical trial is a prospective, randomized, masked to the evaluator to be held at the Department of Ophthalmology, Federal University of Sao Paulo.

Will be included children between 0 and 10 years of age with glaucoma and surgical indication for glaucoma drainage implant. Surgical indication for implantation of Ahmed drainage occurs in some situations: 1) children with primary congenital glaucoma that undergone angular surgery (goniotomy and / or trabeculotomy) who did not respond satisfactorily to surgery, 2) children with glaucoma secondary to aphakia who have the primary indication for implantation of Ahmed drainage, 3) children with glaucoma secondary to other eye disorders where medical treatment is not satisfactory.

A term of consent will be obtained from parents or legal guardians of the child, in which all the risks inherent to the surgical procedure will be clarified. Such risks are proper to antiglaucomatous surgery are:

  1. Early: hypotony, hyphema, tube endothelial touch, choroidal detachment, leakage of aqueous, vitreous hemorrhage, retinal detachment, loss of light perception
  2. late: uncontrolled intraocular pressure, persistent hypotony, scleral patch resorption, extrusion of the tube, retinal detachment, loss of light perception (11-18).

Considering that the selected patient has already the surgical indication for Ahmed drainage implant, the inclusion of this child in the study does not bring additional risks or discomforts to the same.

The model of the drainage implant will be chosen through allocation from a computer-generated random table.

Children enrolled in the study will be divided into two groups (one group will receive the model FP7 and another group will receive the model FP8) with the number of 20 participants in each group, totaling 40 children.

The surgeries will be performed by experienced surgeons from Glaucoma Sector from Department of Ophthalmology, Federal University of Sao Paulo.

The plate of the Ahmed drainage implant will be placed in one of the quadrants selected from the extraocular muscles between 8 and 10 mm away from the corneal limbus. The tube will have its distal portion inserted 2-3mm into the anterior chamber of the eye in the iris plane. The exposed portion of the tube is covered with donor sclera.

The children included in the study will be examined before surgery, which will be measured your visual acuity, biomicroscopy, IOP, Retinography and axial length of the eye. Immediately after surgery, with a compass we will measure the distance between the plate of drainage implant and corneal limbus.

Children will be examined again after 6 months and 1 year of surgery. We will perform the measurement of visual acuity, biomicroscopy, IOP, Retinography, axial length and measurement of the distance from the plate of the implant and corneal limbus. Post-operative examinations will be performed under narcosis, in hospitals (when it is impossible to take measures in an outpatient setting due to lack of cooperation of the child), by a doctor from congenital glaucoma sector who were not involved in the surgical procedure. The examination under narcosis involves risk to the child, which include cough, nausea, vomiting, laryngospasm, bronchospasm, apnea, bradycardia, tachycardia, hypertension, anxiety (19-21).

Two types of outcome will be considered in this study. The primary endpoint is to evaluate the position of the drainage implant plate and if the plate is positioned at a distance ≥ 8 mm from the corneal limbus after 1 year of surgery, considered successful. If the dish drain implant is positioned at a distance \<8 mm from the corneal limbus, we have a failure.

As a secondary outcome, we evaluate the variation in IOP preoperative and postoperative. We will use as a criterion of success an IOP ≤ 21 mm Hg and> 5 mmHg and a 30% reduction of preoperative IOP. If the patient meets these criteria, without the use of eyedrop, classified as complete success. If the use of eyedrop is necessary to meet the criteria, a qualified success will be defined.

For failure criterion is assumed: IOP ≤ 5 mmHg or > 21 mm Hg, even with the use of eye drops, need for further surgery, and / or loss of light perception.

02

Conditions studied

  • Pediatric Glaucoma

Keywords

  • Glaucoma
  • Pediatric
  • Ahmed
  • Congenital
  • FP7
  • FP8
03

In context

Glaucoma

1,818 studies on the registry are indexed under Glaucoma; 231 are open to participants now.

This study's planned enrollment of 40 is below the median of 65 across 1,272 interventional studies indexed under Glaucoma.

Browse Glaucoma studies →

Lead sponsor

Federal University of São Paulo is the lead sponsor of 427 studies on the registry; 22 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Up to 10 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Diagnostic of Pediatric Glaucoma with indication of Ahmed Glaucoma Valve implantation
  • Age from 0 to 10 years old

Exclusion criteria

Exclusion Criteria:

  • Children older then 10 years old
05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Investigator, Outcomes assessor)
Enrollment
40 participants (estimated)

Study arms

  • Active comparator
    FP7 implant

    Device: FP7 Ahmed Glaucoma Drainage Implant

  • Active comparator
    FP8 implant

    Device: FP8 Glaucoma Drainage Implant

Interventions

  • DeviceFP7 Ahmed Glaucoma Drainage Implant

    Ahmed Glaucoma Valve model FP7

  • DeviceFP8 Glaucoma Drainage Implant

    Ahmed Glaucoma Valve model FP8

06

What researchers measure

Primary outcomes

  1. Position of the drainage implant plate

    The primary endpoint is to evaluate the position of the drainage implant plate and if the plate is positioned at a distance ≥ 8 mm from the corneal limbus after 1 year of surgery, considered successful. If the plate is positioned at a distance \<8 mm from the corneal limbus, we have a failure.

    Time frame: After 1 year of surgery

Secondary outcomes

  1. As a secondary outcome, we evaluate the variation in IOP preoperative and postoperative.

    We will use as a criterion of success an IOP ≤ 21 mm Hg and\> 5 mmHg and a 30% reduction of preoperative IOP. If the patient meets these criteria, without the use of eyedrop, classified as complete success. If the use of eyedrop is necessary to meet the criteria, a qualified success will be defined. For failure criterion is assumed: IOP ≤ 5 mmHg or \> 21 mm Hg, even with the use of eye drops, need for further surgery, and / or loss of light perception.

    Time frame: After 1 year of surgery

07

Study locations

1 of 1 sites recruiting
  • Federal University of São Paulo - Ophthalmology Department
    São Paulo, 04023-062, Brazil
    • Camila F Netto, MD · Contact · milanetto@gmail.com · +55-11-99177717
    • Camila F Netto, MD · Principal investigator
    Recruiting
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 8, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01494974
Lead sponsor
Federal University of São Paulo
Responsible party
Camila Fonseca Netto (MD, Federal University of São Paulo) — Principal investigator
First posted
Dec 19, 2011
Start date
Dec 2011
Primary completion
Dec 2015 (estimated)
Last update
Apr 8, 2014

Study contacts

Camila F Netto, MD
Contact
milanetto@gmail.com
+55-1199177717
Camila F Netto, MD
principal investigator · Assistant Doctor at Ophthalmology Department

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Apr 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion